Michaela Liedtke, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Liedtke’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A86006 · Current
Licensed to practise in California · since 2004 · expires 2027-07-31 · Medical Academy of Hannover.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$119,253
Medicare paid this office $119,253 for 395 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 172 | $55,517 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $18,515 | $105 |
| Return visit (30+ min) | 119 | $17,910 | $113 |
| New patient visit (60+ min) | 33 | $6,440 | $195 |
| Long return visit (40+ min) | 31 | $5,661 | $120 |
See all 9 services
| Long return visit (40+ min) | 172 | $55,517 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $18,515 | $105 |
| Return visit (30+ min) | 119 | $17,910 | $113 |
| New patient visit (60+ min) | 33 | $6,440 | $195 |
| Long return visit (40+ min) | 31 | $5,661 | $120 |
| Return visit (30+ min) | 28 | $4,213 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,417 | $155 |
| Hospital discharge day management, more than 30 minutes | 23 | $2,579 | $103 |
| Short return visit (20+ min) | 23 | $2,057 | $86 |
Who their Medicare patients are
395 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 10% · Women 48% · Also on Medicaid 12% · Health risk score 2.37. Above the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 66% · Chronic kidney disease 36% · Heart failure 34% · Coronary heart disease 27% · Atrial fibrillation 25% · Diabetes 22% · Depression 18% · Cancer 15% · COPD 11% · Dementia 5% · Stroke 5%.
The office billed $618,091, Medicare allowed $155,892 and paid $119,253; for 905 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 395 | 905 | 75 | 2.37 | $618,091 | $119,253 |
| 2023 | 408 | 1,098 | 73 | 2.38 | $645,130 | $119,477 |
| 2022 | 364 | 907 | 74 | 2.41 | $531,869 | $94,273 |
| 2021 | 360 | 993 | 73 | 2.41 | $542,224 | $103,448 |
| 2020 | 302 | 811 | 73 | 2.73 | $382,156 | $76,494 |
| 2019 | 284 | 727 | 72 | 2.84 | $174,170 | $69,421 |
| 2018 | 262 | 659 | 71 | 2.89 | $136,096 | $61,474 |
| 2017 | 260 | 867 | 70 | 2.52 | $251,649 | $82,367 |
| 2016 | 250 | 764 | 70 | 2.41 | $246,392 | $74,321 |
| 2015 | 217 | 694 | 72 | 2.26 | $217,253 | $67,389 |
| 2014 | 206 | 740 | 71 | 2.32 | $233,976 | $71,246 |
| 2013 | 191 | 691 | 70 | 2.28 | $207,664 | $61,916 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Long return visit (40+ min) | 166 | $42,843 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $32,725 | $108 |
| Return visit (30+ min) | 156 | $18,375 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,517 | $160 |
| New patient visit (60+ min) | 40 | $6,217 | $155 |
| Hospital discharge day management, more than 30 minutes | 33 | $3,963 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,064 | $73 |
| Short return visit (20+ min) | 37 | $2,196 | $56 |
| Hospital discharge day management, 30 minutes or less | 12 | $911 | $76 |
2022: 8 services
| Long return visit (40+ min) | 149 | $37,748 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $20,685 | $91 |
| Return visit (30+ min) | 134 | $13,796 | $81 |
| New patient visit (60+ min) | 38 | $6,402 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,082 | $174 |
| Short return visit (20+ min) | 50 | $3,207 | $53 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,254 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,568 | $65 |
2021: 11 services
| Long return visit (40+ min) | 127 | $29,975 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $25,285 | $94 |
| Return visit (30+ min) | 122 | $13,824 | $85 |
| New patient visit (60+ min) | 54 | $9,158 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $7,653 | $182 |
| Hospital discharge day management, more than 30 minutes | 44 | $4,903 | $98 |
| Short return visit (20+ min) | 55 | $3,457 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $3,452 | $65 |
| New patient visit (45+ min) | 12 | $1,517 | $126 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $1,095 | $61 |
| Hospital discharge day management, 30 minutes or less | 12 | $832 | $64 |
2020: 11 services
| Long return visit (40+ min) | 119 | $22,116 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $20,064 | $97 |
| Return visit (30+ min) | 72 | $7,103 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $6,297 | $180 |
| New patient visit (60+ min) | 38 | $5,966 | $157 |
| Long return visit (40+ min) | 31 | $3,493 | $103 |
| Hospital discharge day management, more than 30 minutes | 18 | $2,216 | $101 |
| Short return visit (20+ min) | 31 | $1,499 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,421 | $68 |
| New patient visit (45+ min) | 13 | $1,371 | $105 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,109 | $74 |
2019: 9 services
| Long return visit (40+ min) | 116 | $21,803 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $19,432 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $6,975 | $184 |
| New patient visit (60+ min) | 43 | $6,469 | $150 |
| Return visit (30+ min) | 74 | $6,244 | $66 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,785 | $99 |
| Short return visit (20+ min) | 31 | $1,764 | $44 |
| New patient visit (45+ min) | 11 | $1,123 | $102 |
| Hospital discharge day management, 30 minutes or less | 12 | $878 | $68 |
2018: 8 services
| Long return visit (40+ min) | 131 | $27,603 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $11,890 | $94 |
| New patient visit (60+ min) | 43 | $6,472 | $151 |
| Return visit (30+ min) | 56 | $5,198 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,183 | $182 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,173 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,344 | $122 |
| Short return visit (20+ min) | 20 | $1,106 | $43 |
2017: 9 services
| Long return visit (40+ min) | 121 | $29,995 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $27,296 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $6,345 | $181 |
| New patient visit (60+ min) | 44 | $6,184 | $141 |
| Return visit (30+ min) | 50 | $4,159 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,397 | $65 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,866 | $98 |
| Hospital discharge day management, 30 minutes or less | 12 | $795 | $66 |
| Short return visit (20+ min) | 13 | $548 | $39 |
2016: 7 services
| Long return visit (40+ min) | 131 | $31,232 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $22,930 | $92 |
| New patient visit (60+ min) | 64 | $8,972 | $140 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $4,146 | $180 |
| Return visit (30+ min) | 24 | $1,891 | $70 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,459 | $97 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,336 | $121 |
2015: 7 services
| Long return visit (40+ min) | 107 | $27,594 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $22,435 | $93 |
| New patient visit (60+ min) | 48 | $6,617 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,694 | $176 |
| Return visit (30+ min) | 34 | $2,697 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,585 | $122 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,366 | $98 |
2014: 7 services
| Long return visit (40+ min) | 100 | $27,976 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $25,644 | $92 |
| New patient visit (60+ min) | 51 | $7,052 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,777 | $180 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,947 | $122 |
| Return visit (30+ min) | 29 | $1,784 | $51 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,255 | $97 |
2013: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $23,733 | $90 |
| Long return visit (40+ min) | 73 | $18,517 | $92 |
| New patient visit (60+ min) | 45 | $6,241 | $139 |
| Return visit (30+ min) | 59 | $5,349 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,637 | $173 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,313 | $119 |
| Hospital discharge day management, 30 minutes or less | 12 | $773 | $64 |
| Short return visit (20+ min) | 14 | $552 | $34 |
Medicaid work
$6,466 in 2024
Medicaid paid $6,466 for 77 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 77 | $6,466 |
| 2024 | 77 | 1 | 18 | $6,466 |
| 2023 | 138 | 1 | 20 | $8,792 |
| 2022 | 102 | 1 | 17 | $5,817 |
| 2021 | 185 | 2 | 14 | $7,949 |
| 2019 | 12 | 1 | 12 | $557 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 138 | $8,792 |
2022
| Long return visit (40+ min) | 102 | $5,817 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 128 | $5,089 |
| Long return visit (40+ min) | 57 | $2,860 |
2019
| Long return visit (40+ min) | 12 | $557 |
Drugs they prescribed that Part D paid
$2,051,121
Pharmacies billed $2,051,121 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 356) in 2024. At or below the middle of the specialty; the typical hematology clinician is at 4%.
219 generic and fewer than 11 brand-name prescriptions · $2,051,121 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pomalyst | 40 | $962,047 | $24,051 |
| Revlimid | 33 | $590,247 | $17,886 |
| Venclexta | 42 | $373,593 | $8,895 |
| Acyclovir | 78 | $2,281 | $29 |
| Entecavir | 12 | $997 | $83 |
See all 7 drugs
| Pomalyst | 40 | $962,047 | $24,051 |
| Revlimid | 33 | $590,247 | $17,886 |
| Venclexta | 42 | $373,593 | $8,895 |
| Acyclovir | 78 | $2,281 | $29 |
| Entecavir | 12 | $997 | $83 |
| Dexamethasone | 31 | $489 | $16 |
| Gabapentin | 12 | $327 | $27 |
Year by year
| 2024 | 356 | 70 | 0% (0) | None | $2,051,121 |
| 2023 | 372 | 85 | 0% (0) | None | $1,621,890 |
| 2022 | 519 | 87 | None | 37% | $2,885,170 |
| 2021 | 416 | 79 | None | 54% | $3,672,307 |
| 2020 | 400 | 84 | 3% (12) | 52% | $3,452,340 |
| 2019 | 447 | 87 | 3% (14) | 46% | $2,810,582 |
| 2018 | 481 | 93 | 4% (20) | None | $3,450,552 |
| 2017 | 620 | 98 | 8% (48) | 39% | $2,948,275 |
| 2016 | 582 | 86 | 8% (48) | None | $2,141,162 |
| 2015 | 524 | 69 | 7% (35) | None | $1,209,484 |
| 2014 | 633 | 82 | 5% (32) | None | $1,104,790 |
| 2013 | 393 | 59 | 5% (18) | None | $922,801 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Pomalyst | 39 | $802,562 | $20,579 |
| Revlimid | 23 | $436,746 | $18,989 |
| Venclexta | 45 | $307,899 | $6,842 |
| Acyclovir | 83 | $3,001 | $36 |
| Entecavir | 15 | $1,637 | $109 |
| Dexamethasone | 46 | $466 | $10 |
2022: 9 drugs
| Revlimid | 57 | $1,189,140 | $20,862 |
| Pomalyst | 64 | $1,138,958 | $17,796 |
| Venclexta | 28 | $257,688 | $9,203 |
| Sprycel | 11 | $96,269 | $8,752 |
| Atovaquone | 11 | $8,091 | $736 |
| Acyclovir | 104 | $2,521 | $24 |
| Dexamethasone | 74 | $1,124 | $15 |
| Gabapentin | 15 | $206 | $14 |
| Montelukast | 12 | $50 | $4 |
2021: 7 drugs
| Revlimid | 103 | $2,145,886 | $20,834 |
| Pomalyst | 66 | $1,123,254 | $17,019 |
| Venclexta | 18 | $146,404 | $8,134 |
| Acyclovir | 52 | $1,564 | $30 |
| Dexamethasone | 41 | $809 | $20 |
| Entecavir | 13 | $569 | $44 |
| Levofloxacin | 11 | $229 | $21 |
2020: 6 drugs
| Revlimid | 85 | $1,627,562 | $19,148 |
| Pomalyst | 63 | $1,181,421 | $18,753 |
| Sprycel | 11 | $92,633 | $8,421 |
| Acyclovir | 67 | $1,485 | $22 |
| Dexamethasone | 31 | $627 | $20 |
| Gabapentin | 11 | $155 | $14 |
2019: 6 drugs
| Revlimid | 87 | $1,563,488 | $17,971 |
| Pomalyst | 48 | $823,879 | $17,164 |
| Ninlaro | 17 | $180,267 | $10,604 |
| Sprycel | 16 | $106,681 | $6,668 |
| Acyclovir | 91 | $1,531 | $17 |
| Dexamethasone | 39 | $893 | $23 |
2018: 6 drugs
| Revlimid | 106 | $1,972,443 | $18,608 |
| Pomalyst | 51 | $824,286 | $16,162 |
| Venclexta | 11 | $173,327 | $15,757 |
| Ninlaro | 14 | $140,292 | $10,021 |
| Acyclovir | 80 | $1,358 | $17 |
| Dexamethasone | 31 | $661 | $21 |
2017: 12 drugs
| Revlimid | 122 | $1,813,211 | $14,862 |
| Pomalyst | 33 | $482,870 | $14,632 |
| Ninlaro | 20 | $190,145 | $9,507 |
| Jakafi | 11 | $143,390 | $13,035 |
| Xarelto | 11 | $4,966 | $451 |
| Morphine Sulfate Er | 14 | $2,000 | $143 |
| Acyclovir | 96 | $1,301 | $14 |
| Duloxetine | 12 | $1,241 | $103 |
| Dexamethasone | 33 | $525 | $16 |
| Hydromorphone | 14 | $371 | $27 |
| Allopurinol | 11 | $58 | $5 |
| Lorazepam | 12 | $38 | $3 |
2016: 10 drugs
| Revlimid | 97 | $1,182,732 | $12,193 |
| Pomalyst | 30 | $394,945 | $13,165 |
| Ninlaro | 23 | $199,142 | $8,658 |
| Jakafi | 12 | $131,209 | $10,934 |
| Sprycel | 16 | $69,054 | $4,316 |
| Morphine Sulfate Er | 13 | $2,151 | $165 |
| Acyclovir | 104 | $1,155 | $11 |
| Dexamethasone | 62 | $574 | $9 |
| Hydromorphone | 15 | $519 | $35 |
| Lorazepam | 15 | $104 | $7 |
2015: 11 drugs
| Revlimid | 55 | $551,679 | $10,031 |
| Pomalyst | 29 | $346,473 | $11,947 |
| Thalomid | 16 | $144,064 | $9,004 |
| Lyrica | 11 | $3,827 | $348 |
| Nexium | 11 | $2,751 | $250 |
| Acyclovir | 67 | $985 | $15 |
| Dexamethasone | 54 | $531 | $10 |
| Hydromorphone | 12 | $318 | $27 |
| Lorazepam | 23 | $183 | $8 |
| Pantoprazole | 13 | $138 | $11 |
| Sulfamethoxazole-Trimethoprim | 22 | $125 | $6 |
2014: 14 drugs
| Pomalyst | 53 | $516,829 | $9,751 |
| Revlimid | 49 | $456,583 | $9,318 |
| Lyrica | 12 | $3,400 | $283 |
| Acyclovir | 82 | $2,127 | $26 |
| Mercaptopurine | 12 | $1,342 | $112 |
| Dexamethasone | 80 | $998 | $12 |
| Hydrocortisone | 11 | $464 | $42 |
| Gabapentin | 18 | $215 | $12 |
| Sulfamethoxazole-Trimethoprim | 22 | $188 | $9 |
| Pantoprazole | 27 | $184 | $7 |
| Prednisone | 17 | $118 | $7 |
| Amlodipine Besylate | 16 | $61 | $4 |
| Furosemide | 12 | $38 | $3 |
| Trazodone | 11 | $32 | $3 |
2013: 7 drugs
| Revlimid | 56 | $501,369 | $8,953 |
| Pomalyst | 26 | $286,210 | $11,008 |
| Acyclovir | 34 | $715 | $21 |
| Dexamethasone | 45 | $312 | $7 |
| Zolpidem | 14 | $97 | $7 |
| Losartan | 11 | $93 | $8 |
| Allopurinol | 11 | $57 | $5 |
Money from drug and device companies
$8,454 in 2025
| 2025 | 4 | 5 | $8,454 | $8,454 |
| 2024 | 3 | 3 | $10,912 | $10,912 |
| 2023 | 2 | 3 | $4,093 | $4,093 |
| 2022 | 4 | 7 | $11,213 | $12,507 |
| 2021 | 5 | 6 | $11,903 | $11,912 |
| 2020 | 6 | 9 | $19,019 | $19,019 |
| 2019 | 4 | 27 | $35,851 | $45,336 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $2,865 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $2,858 | 2 payments
|
| AstraZeneca UK | None | $2,460 | 1 payment
|
| Taiho Oncology | None | $272 | 1 payment
|
See all 5 published payments
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-10-31 | None | $408 |
| Taiho Oncology | Paid to speak or teach · 2025-10-31 | None | $272 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-08-22 | None | $2,865 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-08-01 | None | $2,450 |
| AstraZeneca UK | Consulting · 2025-06-03 | None | $2,460 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $10,912
| Alexion Pharmaceuticals | None | $4,680 | 1 payment
|
| Jazz Pharmaceuticals | Rylaze | $3,532 | 1 payment
|
| Abbvie | None | $2,700 | 1 payment
|
2023: $4,093
| E.R. Squibb & Sons L.L.C. | None | $3,855 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $238 | 1 payment
|
2022: $12,507
| Kite Pharma | Tecartus | $6,294 | 4 payments
|
| Legend Biotech USA | Carvykti | $2,550 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $2,400 | 1 payment
|
| Janssen Biotech | Tecvayli | $1,263 | 1 payment
|
2021: $11,912
| Takeda Pharmaceuticals U.S.A. | Exkivity | $3,970 | 2 payments
|
| Janssen Biotech | Darzalex | $2,525 | 1 payment
|
| GlaxoSmithKline | Blenrep | $1,950 | 1 payment
|
| Janssen Scientific Affairs | Darzalex | $1,768 | 1 payment
|
| Kite Pharma | Tecartus | $1,700 | 1 payment
|
2020: $19,019
| GlaxoSmithKline | Blenrep | $5,200 | 4 payments
|
| Alnylam Pharmaceuticals | Oxlumo | $4,128 | 1 payment
|
| Genzyme | Sarclisa | $2,517 | 1 payment
|
| Celgene | Revlimid | $2,450 | 1 payment
|
| Kite Pharma | Tecartus | $2,400 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $2,325 | 1 payment
|
2019: $45,336
| Pfizer | Besponsa | $18,360 | 9 payments
|
| Amgen | Kyprolis | $15,852 | 3 payments
|
| Celgene | Revlimid | $9,833 | 10 payments
|
| Janssen Biotech | Darzalex | $1,292 | 5 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ichnos Glenmark Innovation Inc · 2025 | This clinician | $449,061 |
| Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2020 | Their institution | $353,567 |
| Celgene Corporation · A Phase I, Multicenter, Open-Label Study of Cc-986 · 2022 | Their institution | $334,815 |
| Celgene Corporation · Crb-401a Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma (Crb-401) · 2019 | Their institution | $266,254 |
| Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2021 | Their institution | $246,387 |
| Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2022 | Their institution | $193,118 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Open Label, Multicenter Dose Selection Study To Evaluate the Safety and Tolerability of Cael 101 in Patients With Al Amyloidosis · 2024 | Their institution | $174,220 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2024 | Their institution | $133,975 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2023 | Their institution | $109,988 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Open Label, Multicenter Dose Selection Study To Evaluate the Safety and Tolerability of Cael 101 in Patients With Al Amyloidosis · 2023 | Their institution | $102,540 |
| Celgene Corporation · Crb-401 A Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma · 2020 | Their institution | $94,005 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2025 | Their institution | $90,994 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2022 | Their institution | $88,219 |
| PFIZER INC. · A Phase 1 Study of Seabcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2024 | Their institution | $78,917 |
| Celgene Corporation · Phase I Poc Dose Escalation (Cc-98633-Mm-001) - A Phase I, Multicenter, Open-Label Study of Cc-98633, Bcma Targeted Nex-T Chimeric Antigen Receptor (Car) T Cells, in Subjects With Relapsed and/Or Refractory Multiple Myeloma · 2023 | Their institution | $71,733 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2024 | Their institution | $59,328 |
| AstraZeneca Pharmaceuticals LP · A Phase 1/2 Study To Evaluate the Safety and Efficacy of Azd0486 in Adolescent and Adult Participants With Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukaemia · 2025 | Their institution | $56,859 |
| Genentech, Inc. · Beti Multiple Myeloma Phase Ib · 2020 | Their institution | $54,539 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (Vxld) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia · 2019 | Their institution | $37,049 |
| Genentech, Inc. · Beti Multiple Myeloma Phase Ib · 2019 | Their institution | $36,956 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2023 | Their institution | $34,075 |
| IGI Inc · 2024 | This clinician | $31,892 |
| Celgene Corporation · Phiii Ide-Cel Vs Triplet Rrmm 3l · 2020 | Their institution | $29,536 |
| Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2019 | Their institution | $28,759 |
| Gilead Sciences, Inc. · A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma · 2021 | Their institution | $26,977 |
| Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2020 | Their institution | $25,438 |
| Celgene Corporation · Phase I Poc Dose Escalation (Cc-98633-Mm-001) - A Phase I, Multicenter, Open-Label Study of Cc-98633, Bcma Targeted Nex-T Chimeric Antigen Receptor (Car) T Cells, in Subjects With Relapsed and/Or Refractory Multiple Myeloma · 2024 | Their institution | $25,431 |
| Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells · 2024 | Their institution | $23,531 |
| Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells. A Prospective Study for the Long-Term Follow-Up (Ltfu) of Safety and Efficacy for All Pediatric and Adult Participants Exposed To Gene-Modified (Gm) T-Cell Therapy Participating in A Previous Celgene Sponsored Or Celgene Alliance Partner Sponsored Study. · 2025 | Their institution | $21,511 |
| Celgene Corporation · Crb-401 A Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma · 2023 | Their institution | $20,257 |
| Seagen Inc. · A Phase 1 Study of Sea-Bcma in Patients With Relapsed Or Refractory Multiple Myeloma · 2023 | Their institution | $17,293 |
| ABBVIE INC. · First-in-Human Study of the Bcl-2 Inhibitor Abbv-453 in Biomarker-Selected Subjects With Relapsed Or Refractory Multiple Myeloma · 2025 | Their institution | $15,548 |
| ABBVIE INC. · First-in-Human Study of the Bcl-2 Inhibitor Abbv-453 in Biomarker-Selected Subjects With Relapsed Or Refractory Multiple Myeloma · 2024 | Their institution | $13,844 |
| Celgene Corporation · A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered Ag-221 in Subjects With Advanced Hematologic Malignancies With An Idh2 Mutation (Ag-221-C-001) · 2019 | Their institution | $13,056 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2025 | Their institution | $12,384 |
| JAZZ PHARMACEUTICALS INC. · Phase III, Multicenter, Randomized, Trial of Cpx-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) Aml · 2020 | Their institution | $12,224 |
| Celgene Corporation · A Phase I, Multicenter, Open-Label Study of Cc-986 · 2021 | Their institution | $10,806 |
| JAZZ PHARMACEUTICALS INC. · Cltr0310-301 - Phase III Multicenter, Trial of Cpx-351 (Cytarabine:Daunorunbicin) Liposome Injection Vs Cytarabine Daunorunbicin in Patients 60-75 Years of Age · 2020 | Their institution | $10,624 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral Abbv-453 Tablets · 2024 | Their institution | $8,256 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2022 | Their institution | $7,816 |
| Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2022 | Their institution | $7,602 |
| PFIZER INC. · Inotuzumab Ozogamicin Clinical Publication Program · 2020 | This clinician | $6,000 |
| Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2023 | Their institution | $5,683 |
| Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2021 | Their institution | $5,620 |
| Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2024 | Their institution | $4,579 |
| PFIZER INC. · Inotuzumab Ozogamicin Clinical Publication Program · 2023 | This clinician | $3,200 |
| Celgene Corporation · Crb-401 A Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma (Crb-401) · 2019 | This clinician | $2,866 |
| Celgene Corporation · Phase 3, Randomized, Open-Label Trial of Lenalidomide/Dexamethasone With Or Without Elotuzumab in Relapsed Or Refractory Multiple Myeloma · 2025 | Their institution | $2,624 |
| Janssen Research & Development, LLC · A Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared With Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2025 | Their institution | $2,560 |
| Celgene Corporation · A Phase 3, Multicenter, Randomized, Open-Label Stu · 2021 | Their institution | $2,240 |
| JAZZ PHARMACEUTICALS INC. · A Phase II Study of Cpx-351 for Treatment of Aml Or Higher Risk Mds Relapsed Or Refractory To Prior Therapy With Hypomethylating (Hma) Agent · 2020 | Their institution | $2,240 |
| Celgene Corporation · A Phase 3, Multicenter, Randomized, Open-Label Stu - A Phase 3, Multicenter, Randomized, Open-Label Study To Compare the Efficacy and Safety of Bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (Rrmm) (Karmma-3) · 2022 | Their institution | $2,240 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral Abbv-453 Tablets · 2023 | Their institution | $2,100 |
| Adaptive Biotechnologies Corporation · Clonoseq · 2020 | Their institution | $1,800 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral Abbv-453 Tablets · 2022 | Their institution | $949 |
| Celgene Corporation · A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered Ag-221 in Subjects With Advanced Hematologic Malignancies With An Idh2 Mutation · 2020 | Their institution | $640 |
| Celgene Corporation · Crb-401a Phase 1 Study Ofbb2121in Bcma-Expressing Multiple Myeloma · 2021 | Their institution | $448 |
| PFIZER INC. · Inotuzumab Ozogamicin Clinical Publication Program · 2022 | This clinician | $330 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1609918556
- Licence
- CA A86006California A86006: Current · expires 2027-07-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A860060
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-13
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 875 Blake Wilbur, Stanford, CA, 94305